On Friday, Trump named Moncef Slaoui, a former executive at GlaxoSmithKline, and Army General Gustave Perna to lead the effort to develop a coronavirus vaccine, which Trump has dubbed “Operation Warp Speed.” Some have raised a red flag over a possible conflict of interest as Slaoui holds $10 million in stock options at biotech company Moderna, Inc., which recently received $480 million in federal funding for coronavirus vaccine trials.